Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for constipation-predominant irritable bowel syndrome
IRCT20260520069460N1Phase 3Recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jun 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in irritable bowel syndrome (IBS) comparing Colchicine with Placebo (2 arms). Primary endpoints: Frequency of bowel movements per week, Stool consistency and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
colchicine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20260520069460N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260520069460N1.